Melatonin agonists for treatment of sleep and depressive disorders

Main Authors: Srinivasan, Venkataramanujan, Cardinali, Daniel P., Pandi Perumal, Seithikurippu R., Brown, Gregory M.
Format: No definido
Language: English
Published: Universidad Católica Argentina 2011
Subjects:
Online Access: http://bibliotecadigital.uca.edu.ar/repositorio/investigacion/melatonin-agonists-for-treatment-sleep.pdf
Table of Contents:
  • Abstract: Melatonin the hormone secreted by the pineal gland has been effective in improving sleep both in normal sleepers and insomniacs and has been used successfully in treating sleep and circadian rhythm sleep disorders. The lack of consistency in the reports published by the authors is attributed to the differential bioavailabilty and short half-life of melatonin. Sleep disturbances are also prominent features of depressive disorders. To overcome this problem, melatonergic agonists with sleep promoting properties have been introduced in clinical practice. Ramelteon, the MT1/ MT2 melatonergic agonist, has been used in a large number of clinical trials involving chronic insomniacs and has been found effective in improving the total sleep time and sleep efficiency of insomniacs and has not manifested serious adverse effects. The development of another MT1/MT2 melatonergic agonist agomelatine with antagonsim to 5-HT2c serotonin receptors has been found useful not only in treating sleep problems of patients but also as a first line antidepressant with earlier onset of actions in patients with major depressive disorder. An agonist for MT3 melatonin receptor has also been found effective in animal models of depression.